Progress of targeted agents for childhood asthma / 国际儿科学杂志

ABSTRACT

Asthma is a heterogeneous respiratory disorder characterized by airway inflammation that is common in childhood, and some children cannot be controlled with conventional treatment.With the progress on the pathogenesis and endotypes of asthma, targeted agents for T2 asthma, such as omalizumab, mepolizumab, benralizumab and dupilumab have been approved prescripting in pediatric patients of some ages and have achieved good efficacy, becoming the new hope for children with severe and refractory asthma.However, there is a lack of effective targeted medicines for non-T2 asthma.This paper reviews the progress of targeted agents for childhood asthma in recent years for the better application of such drugs by clinical practitioners.